Inflammation, growth factors, and pulmonary vascular remodeling

scientific article published on June 2009

Inflammation, growth factors, and pulmonary vascular remodeling is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JACC.2009.04.006
P698PubMed publication ID19555853
P5875ResearchGate publication ID51437086

P50authorMarc HumbertQ33113039
Joan Albert BarberàQ38545039
Friedrich GrimmingerQ43857421
Ralph T SchermulyQ46115021
Nicholas W MorrellQ60960702
John H. NewmanQ90295091
P2093author name stringLuc Mouthon
Marlene Rabinovitch
Kurt R Stenmark
Evangelos D Michelakis
Sonia C Flores
Michael L Maitland
Paul M Hassoun
Jason X-J Yuan
Peter Lloyd Jones
Norbert F Voelkel
Saadia Eddahibi
P433issue1 Suppl
P407language of work or nameEnglishQ1860
P921main subjectinflammationQ101991
P304page(s)S10-9
P577publication date2009-06-01
P1433published inJournal of the American College of CardiologyQ2984355
P1476titleInflammation, growth factors, and pulmonary vascular remodeling
P478volume54

Reverse relations

cites work (P2860)
Q40073930A 49-Year-Old Man with Subacute Respiratory Failure and Interstitial Lung Opacities
Q37555401A case of pulmonary arterial hypertension associated with adult hemophagocytic lymphohistiocytosis
Q34914604A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion
Q37410202A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents
Q35147704A low mortality model of chronic pulmonary hypertension in sheep
Q91642428A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase
Q49960027A novel piperidine identified by stem cell based screening attenuates pulmonary arterial hypertension via regulating BMP2 and PTGS2 levels
Q30539790A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial
Q33569395Activation of Notch signaling by short-term treatment with Jagged-1 enhances store-operated Ca(2+) entry in human pulmonary arterial smooth muscle cells
Q35412448Activity of Ca -activated Cl channels contributes to regulating receptor- and store-operated Ca entry in human pulmonary artery smooth muscle cells
Q38804583Adhesion Molecules: Master Controllers of the Circulatory System.
Q35219809Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.
Q46280910Adventitial Fibroblast Nox4 Expression and ROS Signaling in Pulmonary Arterial Hypertension
Q33909537Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension
Q34250971Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension
Q28238985Ambrisentan
Q34319305An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension
Q38039046An update on the use of ambrisentan in pulmonary arterial hypertension.
Q83454280Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension
Q36130814Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease
Q38105550Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
Q47975583Apparent Aortic Stiffness in Children With Pulmonary Arterial Hypertension: Existence of Vascular Interdependency?
Q36805200Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension
Q35142695BMP pathway regulation of and by macrophages
Q37776859BMP signaling in vascular development and disease
Q38943124BMP4 inhibits PDGF-induced proliferation and collagen synthesis via PKA-mediated inhibition of calpain-2 in pulmonary artery smooth muscle cells
Q38732718BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators
Q36534321Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and Plasticity in a Rat Model of Traumatic Brain Injury.
Q33593640Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension
Q37822722Bosentan for the treatment of adult pulmonary hypertension
Q37393653Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies
Q36999817CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension
Q42020850CCR5 as a treatment target in pulmonary arterial hypertension
Q36628843CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Q64062342Caffeic Acid Phenethyl Ester Rescues Pulmonary Arterial Hypertension through the Inhibition of AKT/ERK-Dependent PDGF/HIF-1α In Vitro and In Vivo
Q30429980Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease
Q37139375Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells
Q34508068Cardiopulmonary involvement in Puumala hantavirus infection
Q44972307Cell permeability, migration, and reactive oxygen species induced by multiwalled carbon nanotubes in human microvascular endothelial cells
Q23917422Cell permeability, migration, and reactive oxygen species induced by multiwalled carbon nanotubes in human microvascular endothelial cells
Q51132724Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension.
Q23917498Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary arterial hypertension
Q38812727Challenges and opportunities in treating inflammation associated with pulmonary hypertension
Q44490545Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus
Q34199837Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice
Q51743683Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway.
Q37628897Chronic obstructive sleep apnea accelerates pulmonary remodeling via TGF-β/miR-185/CoLA1 signaling in a canine model
Q48140426Circulating angiopoietins in idiopathic pulmonary arterial hypertension
Q36505843Circulating cytokines and growth factors in pediatric pulmonary hypertension
Q35868734Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension
Q47909446Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.
Q37492625Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.
Q45374084Compromised T-Cell Immunity and Virus-like Structure in a Patient with Pulmonary Hypertension
Q37088266Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension.
Q39345470Critical effects of epigenetic regulation in pulmonary arterial hypertension
Q37540613Current challenges in pediatric pulmonary hypertension
Q50976417Cyp2c44 gene disruption is associated with increased hematopoietic stem cells: implication in chronic hypoxia-induced pulmonary hypertension.
Q51815285Cyp2c44-mediated decrease of 15-HETE exacerbates pulmonary hypertension.
Q34518898Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease
Q35835947Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension
Q58087645Diaphragm Muscle Fiber Weakness in Pulmonary Hypertension
Q36535586Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells
Q37620501Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways
Q37070077Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models.
Q90108921Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2α
Q83995042Docosahexaenoic acid monoacylglyceride decreases endothelin-1 induced Ca(2+) sensitivity and proliferation in human pulmonary arteries
Q26996078Drug treatment of pulmonary hypertension in children
Q41166063Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation.
Q37518410Effect of Perflubron-induced lung growth on pulmonary vascular remodeling in congenital diaphragmatic hernia
Q33738592Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension
Q42142797Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat.
Q34021089Egr-1 expression during neointimal development in flow-associated pulmonary hypertension.
Q51140742Elevated serum levels of soluble CD146 in patients with systemic sclerosis.
Q37679940Emerging drugs for pulmonary hypertension
Q89941214Endoplasmic reticulum stress and pulmonary hypertension
Q36888302Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension
Q39040020Endothelial cell signaling and ventilator-induced lung injury: molecular mechanisms, genomic analyses, and therapeutic targets.
Q38873978Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis
Q43429643Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension.
Q37866804Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
Q35684753Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells
Q36963124Enhanced Ca(2+)-sensing receptor function in idiopathic pulmonary arterial hypertension
Q36026281Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine
Q35601475Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension
Q36002233Erythropoietin Attenuates Pulmonary Vascular Remodeling in Experimental Pulmonary Arterial Hypertension through Interplay between Endothelial Progenitor Cells and Heme Oxygenase
Q34524900Estrogens and Development of Pulmonary Hypertension: Interaction of Estradiol Metabolism and Pulmonary Vascular Disease
Q51732363Exercise training in pulmonary arterial hypertension.
Q34182389Fetal production of growth factors and inflammatory mediators predicts pulmonary hypertension in congenital diaphragmatic hernia
Q33859158Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats
Q92555286Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development
Q90379507Formulation and Characterization of Solid Lipid Nanoparticles Loading RF22-c, a Potent and Selective 5-LO Inhibitor, in a Monocrotaline-Induced Model of Pulmonary Hypertension
Q43538214Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension
Q37707674Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension
Q36317485Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension
Q41283956Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension
Q34591167Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats
Q61895125Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar
Q40972077HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension
Q37867676HIV infection and pulmonary arterial hypertension.
Q35208059HMGB1 promotes the development of pulmonary arterial hypertension in rats
Q49249618Helicity and Vorticity of Pulmonary Arterial Flow in Patients With Pulmonary Hypertension: Quantitative Analysis of Flow Formations
Q34920216Heme oxygenase-1 and inflammation in experimental right ventricular failure on prolonged overcirculation-induced pulmonary hypertension
Q38859147Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension.
Q40464742High Pulsatility Flow Induces Acute Endothelial Inflammation through Overpolarizing Cells to Activate NF-κB.
Q36621780High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4
Q37139542Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension
Q42688359Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid
Q46280825Hypoxia and Local Inflammation in Pulmonary Artery Structure and Function
Q35412507Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β.
Q41852292ID3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: its implication for understanding microvascular diseases
Q36527952IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension
Q37281476IL-22 activates oxidant signaling in pulmonary vascular smooth muscle cells
Q33555523IL-32 promotes angiogenesis
Q58730399Identification of a low frequency missense mutation in MUC6 contributing to pulmonary artery hypertension by whole-exome sequencing
Q41713745Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Q54476060Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Q37954724Imatinib mesylate for the treatment of pulmonary arterial hypertension
Q26851508Immune and inflammatory mechanisms in pulmonary arterial hypertension
Q36527847In vivo knockdown of intersectin-1s alters endothelial cell phenotype and causes microvascular remodeling in the mouse lungs
Q34923343Increased Expression of Growth Differentiation Factor-15 in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Q38317794Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension
Q84641191Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension
Q34357428Infections in the immunosuppressed host
Q55155611Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers.
Q54595523Inhalation of Stachybotrys chartarum evokes pulmonary arterial remodeling in mice, attenuated by Rho-kinase inhibitor.
Q35777179Inhibition of Excessive Cell Proliferation by Calcilytics in Idiopathic Pulmonary Arterial Hypertension
Q35572413Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice
Q33925122Inhibition of the Ca(2+)-sensing receptor rescues pulmonary hypertension in rats and mice
Q26860314Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists
Q92239221Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension
Q35994814Interplay of macrophages and T cells in the lung vasculature
Q35014605Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats
Q43458362Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats
Q37032248Iptakalim influences the proliferation and apoptosis of human pulmonary artery smooth muscle cells
Q34897476Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?
Q37787547Key role of the RhoA/Rho kinase system in pulmonary hypertension
Q33793407Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension
Q26853496Leukotrienes in pulmonary arterial hypertension
Q60722882Levosimendan attenuates pulmonary vascular remodeling
Q35057088Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease, and drug action
Q84513994Linking new and old concepts: inflammation meets the Warburg phenomenon in pulmonary arterial hypertension
Q37150873Lung-specific RNA interference of coupling factor 6, a novel peptide, attenuates pulmonary arterial hypertension in rats.
Q38007884Mast cells: an expanding pathophysiological role from allergy to other disorders
Q36960275Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling
Q30234727Mechanisms Underlying HIV Associated Non-infectious Lung Disease.
Q89153101Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension
Q37892336Mechanisms of disease: pulmonary arterial hypertension.
Q46435567Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells
Q42173250Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension.
Q36752368Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension
Q58592398Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology
Q33982509MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts
Q34818972MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells
Q32884516MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension
Q37664516Microvolt T-wave alternans profiles in patients with pulmonary arterial hypertension compared to patients with left ventricular systolic dysfunction and a group of healthy volunteers
Q34576173Modification of hemodynamic and immune responses to exposure with a weak antigen by the expression of a hypomorphic BMPR2 gene
Q26991806Molecular mechanisms of pulmonary arterial remodeling
Q37069397Morphological changes in small pulmonary vessels are associated with severe acute exacerbation in chronic obstructive pulmonary disease.
Q47255437Moving beyond the "Allegory of the Cave" in the assessment of pulmonary arterial hypertension
Q41201643Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism
Q41853468New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis
Q37724192New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation
Q37669139Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension
Q39106214Non-infectious pulmonary disorders in HIV.
Q90032112Noninvasive wave intensity analysis predicts functional worsening in children with pulmonary arterial hypertension
Q51462560Notch activation of Ca2+-sensing receptor mediates hypoxia-induced pulmonary hypertension.
Q28596829Novel biomarkers for risk stratification in pulmonary arterial hypertension
Q37215728Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension.
Q34305561Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.
Q35896190Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions?
Q35798472Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (Sus scrofa domesticus).
Q39411412Optimization of ultrasound contrast agents with computational models to improve selection of ligands and binding strength
Q35412362Overview of current therapeutic approaches for pulmonary hypertension.
Q35926109Oxidant signaling for interleukin-13 gene expression in lung smooth muscle cells
Q37725468PPARgamma activation: a potential treatment for pulmonary hypertension
Q37689190PPARgamma as a potential therapeutic target in pulmonary hypertension
Q35235680Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner
Q37879213Pediatric pulmonary arterial hypertension: current and emerging therapeutic options
Q90420612Perspective: Pathobiological paradigms in pulmonary hypertension, time for reappraisal
Q26859280Perspective: ambient air pollution: inflammatory response and effects on the lung's vasculature
Q35673848Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
Q42282811Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment
Q40303684Pim-1: A new biomarker in pulmonary arterial hypertension
Q102331412Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling
Q90625006Potential Contribution of Carotid Body-Induced Sympathetic and Renin-Angiotensin System Overflow to Pulmonary Hypertension in Intermittent Hypoxia
Q37623819Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension
Q44027694Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension
Q58178283Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells
Q37115093Protection of oral hydrogen water as an antioxidant on pulmonary hypertension
Q88773887Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonary arterial hypertension
Q54946092Pulmonary Arterial Hypertension and Insulin Resistance.
Q58998388Pulmonary Hypertension Is a Probable NO/ONOO− Cycle Disease: A Review
Q26744781Pulmonary Hypertension and Indicators of Right Ventricular Function
Q28085572Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics
Q34095714Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
Q51318362Pulmonary hypertension and Hashimoto's thyroiditis: does a relationship exist?
Q34782622Pulmonary hypertension and the right ventricle-thinking outside the box (Third International Right Heart Failure Summit, part 1).
Q43967338Pulmonary hypertension following haematopoietic stem cell transplantation for primary haemophagocytic lymphohistiocytosis
Q36316371Pulmonary hypertension in patients with Martorell hypertensive leg ulcer: a case control study
Q92282817Pulmonary hypertension in the global population of adolescents and adults living with HIV: a systematic review and meta-analysis
Q37816401Pulmonary vascular disease associated with schistosomiasis
Q36163044Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension
Q91611159Pulmonary vascular mechanical consequences of ischemic heart failure and implications for right ventricular function
Q39057104Pulmonary vascular remodeling in pulmonary hypertension
Q46280803Reactive Oxygen Species in COPD-Related Vascular Remodeling
Q38074770Reactive oxygen species as therapeutic targets in pulmonary hypertension.
Q33803027Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine
Q37139562Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension.
Q34718076Regulation and function of Cav3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells.
Q38870144Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension.
Q97538437Relationship between compliance and pulmonary vascular resistance in pulmonary arterial hypertension
Q38019769Relationships between vascular oxygen sensing mechanisms and hypertensive disease processes
Q35665448Repeated exposure to Aspergillus fumigatus conidia results in CD4+ T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10.
Q38195160Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review
Q35725663Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement?
Q36639482Right ventricular systolic pressure measurements in combination with harvest of lung and immune tissue samples in mice
Q50969268Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension.
Q91792991SGK1 Mediates Hypoxic Pulmonary Hypertension through Promoting Macrophage Infiltration and Activation
Q35062885STIM2 Contributes to Enhanced Store-operated Ca Entry in Pulmonary Artery Smooth Muscle Cells from Patients with Idiopathic Pulmonary Arterial Hypertension
Q41763006Safety and feasibility of obtaining wedged pulmonary artery samples and differential distribution of biomarkers in pulmonary hypertension
Q33965866Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease.
Q64098812Schistosome infection and its effect on pulmonary circulation
Q37133810Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: Detailed study
Q35484295Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
Q36929766Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism
Q34627552Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension
Q41827194Selective inactivation of PTEN in smooth muscle cells synergizes with hypoxia to induce severe pulmonary hypertension
Q34973575Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH.
Q44336945Serum Bcl-2 values in children with pulmonary hypertension.
Q36108039Severe pulmonary hypertension: The role of metabolic and endocrine disorders
Q34297770Sex Hormones and Vascular Protection in Pulmonary Arterial Hypertension
Q54977617Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease.
Q33568826Sex differences in the pulmonary circulation: implications for pulmonary hypertension
Q37133785Signal transduction in the development of pulmonary arterial hypertension
Q33868613Simvastatin as a treatment for pulmonary hypertension trial.
Q37330089Single-cell mass cytometry for analysis of immune system functional states
Q89578350Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension
Q34611424Skeletal muscle abnormalities in pulmonary arterial hypertension.
Q54469933Small platelet microparticle levels are increased in pulmonary arterial hypertension.
Q92126836Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous
Q38112038Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension
Q34535086Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report
Q39202902Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations
Q36747273Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome
Q37475033Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall
Q48179384Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis
Q33950086Systemic sclerosis-associated pulmonary arterial hypertension
Q37995985Targeted approaches to the treatment of pulmonary hypertension.
Q38038222Targeting PDGF pathway in pulmonary arterial hypertension
Q42592575Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension
Q42145272Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change
Q27027610Tenascin-C in development and disease of blood vessels
Q47389219Tetrahydrobiopterin (BH4 ): Targeting endothelial nitric oxide synthase as a potential therapy for pulmonary hypertension
Q47648153The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry
Q90084127The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension
Q35665034The Effects of Antigen-Specific IgG1 Antibody for the Pulmonary-Hypertension-Phenotype and B Cells for Inflammation in Mice Exposed to Antigen and Fine Particles from Air Pollution
Q38066657The Fra-2 transgenic mouse model of systemic sclerosis
Q98770789The Role and Regulation of Pulmonary Artery Smooth Muscle Cells in Pulmonary Hypertension
Q46236716The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Lung Architecture Remodeling
Q33804336The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature
Q52817379The Roles of Genetic Factors in Kawasaki Disease: A Systematic Review and Meta-analysis of Genetic Association Studies.
Q45046014The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension
Q91653814The Search for Disease-Modifying Therapies in Pulmonary Hypertension
Q30473252The adult patient with eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options
Q38112032The adventitia: Essential role in pulmonary vascular remodeling
Q33788493The cancer theory of pulmonary arterial hypertension
Q89941195The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers
Q39294892The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension.
Q39353707The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies
Q26992278The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension
Q34356918The myriad essential roles of microRNAs in cardiovascular homeostasis and disease
Q36644859The right ventricle: biologic insights and response to disease: updated
Q38102555The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models
Q37851851The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.
Q39095141The role of nuclear factor of activated T cells in pulmonary arterial hypertension
Q35517586The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype
Q28359603Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension
Q35038418Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced
Q36049930Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells
Q38349395Treating pulmonary hypertension in pediatrics
Q41970043Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide
Q41895695Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension
Q37806153Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials
Q35015952Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat
Q35085796Unrecognized glucose intolerance is common in pulmonary arterial hypertension
Q37898899Update on pulmonary vascular diseases 2010.
Q36411210Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension
Q35517559Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension
Q37073847WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension
Q40706456Whipple's disease-associated pulmonary hypertension with positive vasodilator response despite severe hemodynamic derangements
Q30248878World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.
Q35576738Xanthine oxidase-derived ROS upregulate Egr-1 via ERK1/2 in PA smooth muscle cells; model to test impact of extracellular ROS in chronic hypoxia
Q95531492[A clinical analysis of 15 children with systemic lupus erythematosus accompanied by pulmonary hypertension]
Q84016564[Innovation for the cure of pulmonary arterial hypertension]
Q36788720mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects

Search more.